Stéphane Kirkesseli

Author

Stéphane Kirkesseli

Sanofi (France)

Also Known As

Kirkesseli, S., S Kirkesseli, S. KIRKESSELI, S. Kirkesseli, Stephane Kirkesseli, Stéphane Kirkesseli

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Sanofi (United States)AVEO Oncology (United States)

About

Stéphane Kirkesseli is an author at Sanofi (France) specializing in medicine, psychiatry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	139
2	Social Sciences	1	1	13
3	Allergy	1	1	39
4	Allergy Medicine	1	1	39
5	Immunology	1	1	39

Stéphane Kirkesseli

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels Sally E. Wenzel, Linda Ford, David S. Pearlman, New England Journal of Medicine	2013	1.3K
Adverse events in phase-I studies: a report in 1015 healthy volunteers M. Sibille, N. Deigat, Annick Janin, European Journal of Clinical Pharmacology Adverse EventsHealth EffectRetrospective Cohort StudyPsychiatryAdverse Event	1998	87
Single‐ and Multiple‐Dose Pharmacokinetics of Riluzole in White Subjects A. Le Liboux, P Lefebvre, Y. Le Roux, The Journal of Clinical Pharmacology	1997	74
Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers John M. Kovarik, Stéphane Kirkesseli, Henri Humbert, British Journal of Dermatology	1992	50
A Comparison of the Pharmacokinetics and Tolerability of Riluzole after Repeat Dose Administration in Healthy Elderly and Young Volunteers A. Le Liboux, Jean‐Paul Cachia, Stéphane Kirkesseli, The Journal of Clinical Pharmacology	1999	49
Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Cyclosporin A (ADI628) after Single and Repeated Administration in Healthy Male and Female Subjects and Asthmatic Patients Shashank Rohatagi, Francoise Calic, Neasa Harding, The Journal of Clinical Pharmacology	2000	49
Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects Henri Humbert, M. D. Cabiac, J. Denouël, Biopharmaceutics & Drug Disposition	1995	40
Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma Virginia Norris, Lee Meng Choong, Duyen Tran, Journal of Allergy and Clinical Immunology AsthmaAllergyAllergy MedicineMedicineImmunology	2005	39
Pharmacokinetics, Pharmacodynamics, and Safety of a Lipid-Lowering Adenosine A1 Agonist, RPR749, in Healthy Subjects Bharti Shah, Shashank Rohatagi, Chandrasekhar Natarajan, American Journal of Therapeutics	2004	15
First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist for endothelial protection L. Bergougnan, Sara Armani, Georg Golor, British Journal of Clinical Pharmacology	2020	14

Page 1